Provided herein is use of an antisense compound complementary to human STAT3 in the manufacture of a medicament for treating B-cell lymphoma in a subject, wherein the medicament is for administration to the subject in a loading phase and then a maintenance phase, wherein the loading phase involves the administration of a total weekly dose of the compound in the range of about 100-750 mg for 1-10 weeks, and the maintenance phase involves administration of a total weekly dose in the range of 100-250 mg for at least 1 week after the loading phase. The STAT (signal transducers and activators of transcription) family of proteins are DNA binding proteins that play a dual role in signal transduction and activation of transcription.
